Ποια είναι η τιμή για Dong-A ST Co., Ltd. (170900)

Η τιμή για Dong-A ST Co., Ltd. (170900) είναι $25.52

Ποια είναι η κεφαλαιοποίηση αγοράς για Dong-A ST Co., Ltd. (170900)

Η κεφαλαιοποίηση αγοράς για Dong-A ST Co., Ltd. (170900) είναι $246.07M

Dong-A ST Co., Ltd. (170900) Τιμή και Κεφαλαιοποίηση Αγοράς

Dong-A ST Co., Ltd. is a global enterprise focused on the research, development, production, and commercialization of a broad spectrum of pharmaceutical products and medical devices. The company's diverse portfolio of ethical drugs targets various medical conditions, including tuberculosis (with treatments like Closerin and Terizidone), neutropenia in chemotherapy patients (such as Dulastin and Leucostim), and anemia stemming from chronic renal failure (Eporon). Its robust oncology offerings feature Gemcit for cancers affecting the lung, pancreas, breast, bladder, and ovaries; Mainta for non-small cell lung cancer and malignant pleural mesothelioma; and Monotaxel, indicated for breast, prostate, head, neck, and gastric adenocarcinoma, among others. Additionally, Dong-A ST provides solutions for infertility and anovulation (Gonadopin), growth hormone deficiency and idiopathic short stature (Growtropin II), functional dyspepsia (Motilitone), gastritis (Stillen), diabetes (Suganon), and erectile dysfunction (Zydena). The company also actively participates in pharmaceutical licensing, encompassing both the acquisition and out-licensing of drugs. Its medical device segment includes advanced technological equipment, customized products, and specialized artificial cardiac circuit sets essential for complex open-heart surgeries. Dong-A ST Co., Ltd. was established in 1932 and is headquartered in Seoul, South Korea.

Η τιμή για 170900	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$569,323 $246.07M	NVDA	$5.490T	+2,231,130.10%
$494,035 $246.07M	AAPL	$4.764T	+1,936,069.93%
$418,425 $246.07M	GOOG	$4.035T	+1,639,745.05%
$383,895 $246.07M	MSFT	$3.702T	+1,504,420.85%
$284,149 $246.07M	AMZN	$2.740T	+1,113,505.68%

Η τιμή για 170900

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$569,323 $246.07M